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Anal canal cancer is rare, accounting for only 1.3% of all gastrointestinal tract malignancies. Prostate cancer incidence is much
higherandaccountsfor27.6%ofallmalignanciesinmen.Treatmentguidelinesforanalcancerinvolveradiotherapytotheprimary
site and draining lymphatics while treatment for prostate cancer can also include pelvic radiotherapy. The literature is silent on
the optimum course of action when these two malignancies are found synchronously or metachronously. Herein, we report a
case of a patient diagnosed with intermediate risk prostate cancer who, prior to deﬁnitive therapy for this ﬁrst malignancy, was
also diagnosed with anal canal cancer. We conclude that a simultaneous approach with radiation therapy and chemotherapy with
subsequent boost to the prostate is recommended. Screening for synchronous prostate cancer in male anal canal cancer patients is
probably indicated and may preclude suboptimal treatment for a second occult primary.
1.Introduction
Squamous cell carcinoma of the anal canal is rare and
accounted for only 0.3% of the total estimated new cases
of cancer in the USA in 2010. In men, this percentage
was even lower at 0.25%, comprising an estimated 2,000
cases, and accounting for only 1.3% of all gastrointestinal
tract malignancies. Conversely, prostate cancer incidence is
more than 100times higher and accounts for approximately
27.6% of all malignancies in men [1]. Established treatment
guidelines for localized anal cancer involve radiotherapy to
the primary site and draining lymphatics to include the
pelvic and inguinal nodes [2]a sw e l la st h eu s eo fc o n c u r r e n t
systemic chemotherapy [3]. The use of pelvic radiotherapy
is also well established for the treatment of localized prostate
cancer, with or without concurrent hormonal therapy [4].
Unfortunately, the literature is silent on the optimum
course of action when these two malignancies are found
synchronously, or metachronously, before deﬁnitive therapy
has been initiated for either.
Herein,wereportacaseofapatientdiagnosedwithinter-
mediate risk prostate cancer who, prior to deﬁnitive therapy
for this ﬁrst malignancy, was also diagnosed with early-stage
anal canal cancer.
2. Case Presentation
The patient was a 68-year-old human-immunodeﬁciency
virus- (HIV-) negative African-American male who pre-
sented for consideration of radiation therapy for prostate
cancer: clinical stage T1c, Gleason score 4 + 3 = 7 (Figures 1
and 2), prostate speciﬁc antigen (PSA) 14.5 nanogram/
deciliter. Further workup with a bone scan and a computed
tomography (CT) scan of the abdomen and pelvis were
negative for any evidence of metastatic disease. He was
oﬀered deﬁnitive radiation therapy, but elected instead to
pursue deﬁnitive surgery. However, due to his numerous,
poorly controlled comorbidities including diabetes mel-
litus, hypertension, renal insuﬃciency, gout, and coro-
nary/peripheral artery disease, he was started on androgen2 Case Reports in Oncological Medicine
Figure 1: Prostate adenocarcinoma from biopsy (hematoxylin and
eosin, 200x).
Figure 2: Prostate adenocarcinoma from biopsy (hematoxylin and
eosin, 400x).
deprivation therapy with the gonadotropin-releasing hor-
mone agonist leuprolide as a temporizing maneuver while
optimizing management of these conditions prior to surgery.
After 18 months of hormonal monotherapy and prior
to commencing his planned open radical prostatectomy,
he developed scant hematochezia. Evaluation via physical
exam, colonoscopy, and biopsy revealed a 1.5centimeter
invasive squamous cell carcinoma (Figure 3) at the anorectal
junction. Staging studies including a positron emission
tomography (PET)/CT scan showed a T1 N0 anal canal
cancer, Stage I. There was no evidence of metastatic disease
from either primary malignancy. He was evaluated in a mul-
tidisciplinary setting with surgical, medical, and radiation
oncologists; the decision was made to treat both primaries
simultaneously.
He underwent a planning CT in the supine position.
Due to the relative lack of experience at the time in treating
analcanalcancerwithintensity-modulatedradiationtherapy
(IMRT), his initial plan consisted of a wide anterior-
posterior (AP)/narrow posterior-anterior (PA) ﬁeld arrange-
ment to treat the primary pelvic disease and draining lymph
nodes with concurrent mitomycin-C and capecitabine, a
common approach for anal canal cancer treatment. Six
MV photons were used with a 1-centimeter bolus material
applied daily to the anterior inguinal nodal region to ensure
nodal coverage to a dose of 3,060centigray (cGy) using
180cGy fractions. The superior border of the ﬁeld was
moved inferiorly from the L5/S1 interspace to the level of the
true pelvis, and the dose was carried to 3,600cGy. The lateral
ﬁeld borders of the AP ﬁeld were then narrowed to match
the divergence of the PA ﬁeld at midplane, and treatment
Figure 3: Squamous cell carcinoma in situ of the anus with
underlying invasion from biopsy (hematoxylin and eosin, 200x).
was continued to 5,040cGy to complete the therapy for his
anal canal cancer. At this point, an IMRT boost was planned
to encompass the prostate and proximal seminal vesicles
with margin to bring the dose for his prostate malignancy
to 7,380cGy. His treatment progressed as planned although
a one-week treatment break was required due to moist
desquamation in the bilateral inguinal and intergluteal areas.
Otherwise, he completed the combined modality therapy
with no signiﬁcant gastrointestinal or genitourinary toxicity.
His androgen deprivation therapy was continued during his
radiation therapy and then stopped. Notwithstanding his
18 months of temporizing hormonal therapy, the hormonal
therapy administered during his deﬁnitive radiation therapy
could be considered to be most consistent with short-term
neoadjuvant and hormonal therapy which is supported by
several randomized trials for men with intermediate risk
disease [5, 6]. He has been followed regularly since that time
with routine physical exams (including regular anoscopy)
and serum PSA checks. At his last followup, 18 months after
completing simultaneous therapy for both malignancies, he
has no evidence of disease recurrence of either cancer and no
signiﬁcant gastrointestinal or genitourinary toxicity from his
therapy.
3. Discussion
Accepted treatment regimens for both prostate cancer and
anal canal cancer are well established. However, the treat-
mentofeithermalignancywithradiationtherapyinisolation
wouldlikelyprecludeoptimumfuturetreatmentoftheother,
either by removing further pelvic radiotherapy as an option
or making deﬁnitive surgery substantially more diﬃcult due
to pelvic adhesions.
In this case, the patient was ﬁrst diagnosed with prostate
cancer. The deﬁnitive therapy that he selected, radical
prostatectomy, was delayed while attempting to optimize
management of his multiple comorbidities. Given the sever-
ityoftheseconditions,considerationwasgiventonotinitiate
any therapy at all for his prostate cancer, or at most, simply
continuing his hormonal therapy alone which was eﬀectively
controlling his serum PSA. However, with a PSA greater than
10 and a Gleason sore of 4+3 = 7 in greater than 50% of the
cores obtained, he was stratiﬁed as “high-intermediate” risk
[7] and both the patient and the treating team considered
deﬁnitive therapy important to pursue.Case Reports in Oncological Medicine 3
Had our patient initially selected deﬁnitive radiation
therapy (with or without concurrent hormonal therapy) for
treatment of his prostate cancer, optimal therapy for his
metachronous anal canal cancer would have been compro-
mised as additional pelvic radiotherapy would have been
contraindicated;abdominoperinealresection(APR)withthe
associated permanent colostomy would likely have been
required. Due to the markedly disparate levels of incidence
of prostate and anal canal cancer, screening for anal canal
cancer in a patient diagnosed with prostate cancer with
anything other than a digital rectal exam (DRE) is not
routinely indicated. However, especially in older men, the
converse is probably not true. Current National Comprehen-
sive Cancer Committee (NCCN) guidelines for the workup
and staging of anal canal cancer do recommend a DRE
and an abdominal/pelvic CT scan, but do not speciﬁcally
recommend the additional screening step of a serum PSA
test [2]. Had our patient’s anal canal cancer been diagnosed
ﬁrst, his prostate cancer would not have been detected with a
DRE; he was had clinical stage T1c at diagnosis. Additionally,
his staging pelvic CT scan failed to show any concerning
abnormalities in or around his prostate. The only indication
of prostate cancer would have been his elevated serum PSA.
Terris and Wren reported their results of a single
institution study in which 20 consecutive men scheduled for
APR for a diagnosis of a colorectal malignancy were screened
for prostate cancer with DRE and PSA prior to undergoing
the APR. Six men were found to have an elevated PSA; two
of these men were also noted to have an abnormal DRE.
Prostate biopsy in these six men demonstrated that half
of them had synchronous prostate cancer (15.8% of those
screened). The authors recommended that male patients
aged 50 years or older with at least a ten-year life expectancy
scheduled for APR be screened for prostate cancer. This
screening procedure detected a substantial percentage of
menwithasynchronousmalignancywhosedetectionand/or
treatment could have been hindered by the pending curative
procedure for their colorectal malignancy [8]. Therefore,
whilenotspeciﬁcallyrecommendedintheNCCNguidelines,
it appears to make intuitive sense to check a serum PSA
in older men with anal canal cancer to preclude initiating
therapy that may impact the ability to treat a synchronous
or metachronous pelvic malignancy, given the increased
incidence of prostate cancer in this cohort.
An analogous clinical scenario is the recommendation
for a thorough gynecological exam including screening for
cervical cancer in women diagnosed with anal canal cancer
prior to the initiation of therapy, as treatment of all but the
very earliest stages of this malignancy also involves pelvic
radiation therapy [2]. This recommendation is based on
the strong association of human papilloma virus (HPV)
infection with both anal canal and cervical cancer. The data
for an association between HPV infection and an increased
risk of prostate cancer is mixed and controversial; examples
includearecentserologyinvestigationofmenontheProstate
Cancer Prevention Trial [9] which failed to demonstrate an
association, and a case-control study that screened prostate
biopsy tissue DNA and RNA for the presence of HPV viral
genomes that demonstrated a positive association [10].
In conclusion, anal canal cancer is a relatively rare
malignancywhoseoptimumtreatmentinvolvespelvicradio-
therapy with concurrent systemic chemotherapy. Prostate
cancerisamuchmorecommonmalignancywhosedeﬁnitive
treatment may be compromised by prior pelvic radiother-
apy. As the literature is silent on the optimal treatment
of synchronous or metachronous presentation of these
malignancies, a simultaneous approach with pelvic radiation
therapy and systemic chemotherapy with subsequent ﬁeld
adjustments to boost the prostate and seminal vesicles to
a higher deﬁnitive dose is recommended. If available, the
use of intensity-modulated radiation therapy can also be
considered [11]. Screening for synchronous prostate cancer
in male patients diagnosed with anal canal cancer via DRE
and serum PSA is probably indicated and may preclude
suboptimal treatment for a second occult primary.
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